Prescott Group Capital Management L.L.C. Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX

Prescott Group Capital Management L.L.C. increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 45.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 869 shares of the pharmaceutical company’s stock after purchasing an additional 272 shares during the quarter. Prescott Group Capital Management L.L.C.’s holdings in Vertex Pharmaceuticals were worth $387,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Sound View Wealth Advisors Group LLC raised its stake in shares of Vertex Pharmaceuticals by 2.7% in the second quarter. Sound View Wealth Advisors Group LLC now owns 3,624 shares of the pharmaceutical company’s stock worth $1,613,000 after buying an additional 94 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Vertex Pharmaceuticals by 1,251.2% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 206,095 shares of the pharmaceutical company’s stock valued at $91,753,000 after acquiring an additional 190,842 shares during the period. Delta Financial Advisors LLC increased its holdings in Vertex Pharmaceuticals by 15.5% in the 2nd quarter. Delta Financial Advisors LLC now owns 788 shares of the pharmaceutical company’s stock worth $351,000 after acquiring an additional 106 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Vertex Pharmaceuticals by 7.3% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 524,925 shares of the pharmaceutical company’s stock worth $233,697,000 after acquiring an additional 35,858 shares in the last quarter. Finally, Freemont Management S.A. raised its stake in Vertex Pharmaceuticals by 244.8% during the 2nd quarter. Freemont Management S.A. now owns 20,000 shares of the pharmaceutical company’s stock worth $8,904,000 after acquiring an additional 14,200 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 1.6%

Shares of VRTX stock opened at $409.47 on Friday. The company’s fifty day simple moving average is $404.55 and its two-hundred day simple moving average is $429.56. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $519.88. The stock has a market cap of $104.98 billion, a P/E ratio of 29.27 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm had revenue of $3.08 billion during the quarter, compared to analyst estimates of $3.05 billion. During the same quarter last year, the business posted $4.38 earnings per share. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the subject of a number of recent analyst reports. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price target for the stock from $458.00 to $456.00 in a research report on Thursday, September 25th. JPMorgan Chase & Co. lifted their target price on shares of Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Raymond James Financial initiated coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They issued a “market perform” rating for the company. UBS Group decreased their price target on Vertex Pharmaceuticals from $553.00 to $546.00 and set a “buy” rating on the stock in a report on Friday. Finally, Wall Street Zen downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $489.10.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.